Price
$0.17
Increased by +2.94%
Dollar volume (20D)
9.11 K
ADR%
17.06
Shares float
7.48 M
Shares short
79.35 K [1.06%]
Shares outstanding
8.31 M
Market cap
1.35 M
Beta
-0.05
Price/earnings
0.45
20D range
0.16 0.23
50D range
0.13 0.23
200D range
0.12 3.39

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.

Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.

The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).

It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML.

Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 13, 25 -0.40
Increased by +91.80%
-0.38
Decreased by -5.26%
Mar 6, 25 -0.07
Increased by +99.01%
-0.37
Increased by +81.08%
Nov 13, 24 -0.70
Decreased by -118.75%
-1.02
Increased by +31.37%
Aug 14, 24 -1.16
Decreased by -118.87%
-1.54
Increased by +24.68%
May 14, 24 -4.88
Decreased by -639.39%
-4.54
Decreased by -7.49%
Mar 7, 24 -7.05
Decreased by -1.26 K%
-5.40
Decreased by -30.56%
Nov 13, 23 -0.32
Increased by +34.69%
-0.34
Increased by +5.88%
Aug 14, 23 -0.53
Decreased by -26.19%
-0.52
Decreased by -1.92%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 0.00
Decreased by N/A%
-2.85 M
Increased by +9.66%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by -100.00%
-2.75 M
Increased by +18.36%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-2.12 M
Increased by +33.89%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-1.87 M
Increased by +55.86%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-3.16 M
Increased by +39.91%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 274.00 K
Increased by +N/A%
-3.37 M
Increased by +14.55%
Decreased by -1.23 K%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-3.20 M
Increased by +9.22%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-4.23 M
Decreased by -40.85%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY